Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
Source: Leukemia Research - Category: Hematology Authors: Devendra Hiwase, Peter Tan, James D ’Rozario, John Taper, Anthony Powell, Ian Irving, Matthew Wright, Susan Branford, David T. Yeung, Luke Anderson, Othon Gervasio, Carly Levetan, Will Roberts, Ann Solterbeck, Robert Traficante, Timothy Hughes Tags: Research paper Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Nilotinib | Study | Tasigna